Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘novel’

Development of novel therapeutics to address global unmet medical needs

Posted by fidest press agency su giovedì, 12 settembre 2019

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or “S. aureus”) including methicillin-resistant Staphylococcus aureus (MRSA, i.e., one of the commonly known “super-bugs”) based on a novel anti-virulence approach.The ALS-4 candidate has been progressing well and the first series of GLP toxicology studies have been completed through an appointed North American based contract research organization (CRO). In particular, ALS-4 candidate did not show any mutagenicity in the in vitro Ames tests. ALS-4 development is on track and the company targets to submit the related IND in the first half year of 2020 and a hybrid Phase 1 clinical study is currently planned in North America with both healthy volunteers and patients to obtain preliminary efficacy readout.
S. aureus is a bacteria which is a leading cause of blood, lung, skin, bone and device-related infections, as well as toxin-related diseases1. It is estimated that patients with S. aureus bacteremia have an average mortality rate of 30%2 and that it is responsible for causing more deaths than AIDS, tuberculosis and viral hepatitis combined3. MRSA and vancomycin-intermediate and resistant S. aureus have also been classified by the World Health Organization (WHO) as high priority pathogens for research and development

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop a Series of Novel ADCs

Posted by fidest press agency su mercoledì, 10 aprile 2019

Celltrion (KRX:068270) and the Canada-based iProgen Biotech Inc. announced to agree to partner for the development of novel ADCs against validated antibody targets, including HER21 and CD202. The terms of the partnership agreement include: (1) Celltrion manufactures and supplies four recombinant antibodies to iProgen, among which two are HER2 and CD20 targeting, selected by Celltrion, and two additional targets to be selected by iProgen, (2) Celltrion provides supports for the Chemistry, Manufacturing, and Control (CMC) activities for the IND application and the Phase-1 clinical trial, (3) iProgen conducts the Phase-1 clinical trial using these drug candidates, and (4) upon completion of Phase 1, Celltrion has the right of first negotiation on these drug candidates for global in-licensing.
The antibodies encompassing iProgen’s proprietary delivery technology, Antibody Delivery Enhancing Domain (ADED) is expected to increase anti-tumor efficacy by enhancing the drug delivery and internalization to cancer cells. The ADED technology is applied to anti-HER2 ADCs to potentially treat not only the breast cancer patients with high levels of HER2 expression more effectively but also those with low levels with no approved targeted therapies. In addition to HER2, other tumor antigens may be therapeutically targeted by ADCs that embody this technology.The representative of Celltrion said, “Celltrion has been searching for novel technologies that could expand the use of existing antibody therapeutics and produce biobetters and next-generation biotherapeutics, in order to bolster its pipeline outside biosimilars and small molecules,” adding that “We will keep on enriching our pipeline to include a panel of oncology drugs, as part of the effort to improve patients’ lives worldwide.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Joyce’s Fiction and the New Rise of the Novel

Posted by fidest press agency su martedì, 31 gennaio 2017

james-joyceRoma Giovedì 2 Febbraio 2017, ore 9:30 / 3 Febbraio 2017 Dipartimento di Lingue, Letterature e Culture Straniere, Sala Ignazio Ambrogio, Aula C Via del Valco San Paolo 19. Joyce’s Fiction and the new Rise of the Novel (La narrative di Joyce e la rinascita del romanzo) è il titolo del decimo convegno organizzato da The James Joyce Italian Foundation in collaborazione con il Dipartimento di Lingue, Culture e Letterature, e che si svolgerà nei giorni 2 e 3 febbraio prossimi, in occasione della data del compleanno dello scrittore irlandese, James Joyce. Il tema principale vuole sottolineare da una parte il rapporto del romanzo di Joyce con la nascita (Rise) del romanzo inglese nel Diciottesimo secolo, una linea di analisi proposta tra i primi da Giorgio Melchiori negli anni ’50 del secolo scorso. Dall’altra si riflette sull’eredità della narrativa joyceana nell’ambito della nuova-nascita, nella rinascita del romanzo oggi. Gli interventi molto numerosi, molto spesso di giovani studiosi non solo italiani – vengono infatti dall’Europa, dagli USA, dai paesi dell’Est, da Israele, dalla Nuova Zelanda – sono stati organizzati sullo schema di due serie di panel paralleli, preceduti dalla conferenza di apertura su Finnegans Wake tenuta dal professore Finn Fordham dell’Università di Londra e intervallati dagli interventi di alcuni studiosi prestigiosi. Uno spazio è stato riservato al ricordo dei soci onorari di The James Joyce Italian Foundation, scomparsi negli ultimi anni: Umberto Eco, Rosa Maria Bosinelli, Jacqueline Risset.

Posted in Roma/about Rome, Università/University | Contrassegnato da tag: , , | Leave a Comment »